SCHEMBL476242

SCHEMBL476242

NC(=O)C1(c2ccccc2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.60
TSHR P16473 1/20 0.60
POLB P06746 1/20 0.59
ALDH1A1 P00352 4/20 0.58
CYP2D6 P10635 3/20 0.58
NPFFR1 Q9GZQ6 1/20 0.53
NPFFR2 Q9Y5X5 1/20 0.53
OPRM1 P35372 2/20 0.52
CHRM2 P08172 1/20 0.52
CHRM3 P20309 1/20 0.52
CYP3A4 P08684 2/20 0.51
HSD17B10 Q99714 1/20 0.51
CCR3 P51677 1/20 0.51
KDM4E B2RXH2 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 2/20 0.50
KMT2A Q03164 2/20 0.50
SIGMAR1 Q99720 1/20 0.50
MAPK1 P28482 2/20 0.49
MEN1 O00255 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2158958 0.98 POLB (0.61) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL10567546 0.91 TSHR (0.54) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL2702170 0.90 ALDH1A1 (0.55) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL3406327 0.90 CYP3A4 (0.58) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL2699787 0.88 CHRM2 (0.55) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL2794291 0.88 OPRL1 (0.64) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL3411033 0.87 CHRM2 (0.57) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL31567152 0.86 TSHR (0.53) OPRL1TSHRPOLBALDH1A1CYP2D6
Hydrochloric Acid SCHEMBL2793069 0.86 POLB (0.65) OPRL1TSHRPOLBALDH1A1CYP2D6
SCHEMBL5330651 0.85 CYP2D6 (0.61) OPRL1TSHRPOLBALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409457-B1 METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE SANOFI AVENTIS (FR) 2006-08-02 EP claimed
US-6916929-B2 Method for preparing 4-methylamino-4-phenylpiperidine SANOFI-SYNTHELABO (FR) 2005-07-12 US claimed
US-20040181071-A1 Method for preparing 4-methylamino-4-phenylpiperidine SANOFI-AVENTIS (FR) 2004-09-16 US claimed
EP-1409457-A1 METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE Sanofi-Aventis (FR) 2004-04-21 EP claimed
WO-2003008381-A1 METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE SANOFI-SYNTHELABO (FR) 2003-01-30 WO claimed
EP-3914246-A1 LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS ICM (Institut du Cerveau et de la Moelle Épinière) (FR) 2021-12-01 EP disclosed
WO-2020152212-A1 LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) 2020-07-30 WO disclosed
EP-2411383-B1 DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
EP-2324015-B1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-07-03 EP disclosed
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2411383-A1 DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-02-01 EP disclosed
EP-1409457-A1 METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE Sanofi-Aventis (FR) 2004-04-21 EP disclosed
WO-2003008381-A1 METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE SANOFI-SYNTHELABO (FR) 2003-01-30 WO disclosed
EP-0743940-B1 NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT ASTRA AB (SE) 2000-05-03 EP disclosed
US-5968953-A FOR SIDE EFFECT REDUCTION ASTRA AB (SE) 1999-10-19 US disclosed
US-5756520-A N-SUBSTITUTED 4-PHENYL-4-CARBOXAMIDE-PIPERIDINE COMPOUNDS ARE ADMINISTERED EPIDURALLY OR INTRATHECALLY FOR CONTROLLING NERVE BLOCKADE IN HUMANS ASTRA AB (SE) 1998-05-26 US disclosed
WO-1998007722-A1 QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONIST PFIZER LIMITED (GB) 1998-02-26 WO disclosed
EP-0743940-A1 NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT Astra Aktiebolag (SE) 1996-11-27 EP disclosed
WO-1995021821-A1 NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT ASTRA AKTIEBOLAG (SE) 1995-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181071-A1 Method for preparing 4-methylamino-4-phenylpiperidine KDM4C, PAH, ALKBH5 OPRL1 1159/4885TSHR 4181/4885POLB 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.